A Phase 1 Study to Determine the Safety and Pharmacokinetics of Brivanib in Chinese Subjects With Advanced Hepatocellular Carcinoma (HCC).
Phase of Trial: Phase I
Latest Information Update: 05 Aug 2014
At a glance
- Drugs Brivanib alaninate (Primary)
- Indications Liver cancer
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 07 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 May 2013 Planned end date changed from 1 Mar 2014 to 1 Aug 2013 as reported by ClinicalTrials.gov.
- 07 Sep 2012 Planned End Date changed from 1 Dec 2012 to 1 Mar 2014 as reported by ClinicalTrials.gov.